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Results
Costs and benefits were combined using an incremental cost-effectiveness ratio (additional cost per life year gained). For HBeAg positive patients, when pegylated interferon was compared with interferon the average cost per life year gained was $100,752.24. For these patients lamivudine was found to be dominated by interferon (lamivudine was more costly and less effective).
For HBeAg negative patients, when interferon was compared with lamivudine the incremental cost-effectiveness ratio was $15,766.90 per life year gained. For these patients pegylated interferon was found to be dominated by interferon (pegylated interferon was more costly and less effective).
One-way sensitivity analysis indicated that the results were sensitive to variations in the probability of transition from chronic hepatitis B to compensated cirrhosis, discount rate and medicine prices. Results of the probabilistic sensitivity analysis showed that at willingness to pay thresholds set by the World Health Organisation, interferon was the most costeffective intervention for both HBeAg positive and negative patients.
